6 July 2018 - - San Diego, California-based central nervous system disorders therapeutics developer Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has received FDA approval of a new capsule dose formulation and a new tablet strength of Nuplazid (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with Parkinson's disease psychosis, the company said.
The FDA approval of a 34mg Nuplazid capsule formulation will meet the recommended daily dose in a single small capsule versus the current administration of two 17mg tablets.
In addition, the FDA approval of a 10 mg tablet provides an optimized lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3A4 inhibitors which can inhibit the metabolism of Nuplazid.
Nuplazid is a non-dopaminergic, selective serotonin inverse agonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson's disease psychosis. Acadia discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize Nuplazid.
Acadia is a biopharmaceutical company focused on the development and commercialisation of innovative medicines to address unmet medical needs in central nervous system disorders.